Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free HBP Stock Alerts

Helix BioPharma (HBP) Competitors

Helix BioPharma logo
C$1.40 +0.03 (+2.19%)
As of 07/3/2026 12:37 PM Eastern
Compare

HBP vs. PLI, ABCN, EMC, TH, and BCT

Should you buy Helix BioPharma stock or one of its competitors? MarketBeat compares Helix BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Helix BioPharma include ProMetic Life Sciences (PLI), VIVO Cannabis (ABCN), Emblem (EMC), Theratechnologies (TH), and BriaCell Therapeutics (BCT). These companies are all part of the "biotechnology" industry.

How does Helix BioPharma compare to ProMetic Life Sciences?

Helix BioPharma (TSE:HBP) and ProMetic Life Sciences (TSE:PLI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

Helix BioPharma has higher earnings, but lower revenue than ProMetic Life Sciences. Helix BioPharma is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A
ProMetic Life SciencesC$39.91M0.00-C$1.47B-C$63.06N/A

0.0% of Helix BioPharma shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ProMetic Life Sciences' return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -21.54% -279.98%
ProMetic Life Sciences N/A N/A N/A

In the previous week, Helix BioPharma had 1 more articles in the media than ProMetic Life Sciences. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for ProMetic Life Sciences. Helix BioPharma's average media sentiment score of 1.38 beat ProMetic Life Sciences' score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the media.

Company Overall Sentiment
Helix BioPharma Positive
ProMetic Life Sciences Neutral

Summary

Helix BioPharma beats ProMetic Life Sciences on 6 of the 10 factors compared between the two stocks.

How does Helix BioPharma compare to VIVO Cannabis?

VIVO Cannabis (CVE:ABCN) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VIVO CannabisN/AN/AN/AN/AN/A
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A

In the previous week, Helix BioPharma had 1 more articles in the media than VIVO Cannabis. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for VIVO Cannabis. Helix BioPharma's average media sentiment score of 1.38 beat VIVO Cannabis' score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the news media.

Company Overall Sentiment
VIVO Cannabis Neutral
Helix BioPharma Positive

0.0% of Helix BioPharma shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

VIVO Cannabis' return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
VIVO CannabisN/A N/A N/A
Helix BioPharma N/A -21.54%-279.98%

Summary

Helix BioPharma beats VIVO Cannabis on 4 of the 6 factors compared between the two stocks.

How does Helix BioPharma compare to Emblem?

Emblem (CVE:EMC) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

Emblem has higher revenue and earnings than Helix BioPharma. Helix BioPharma is trading at a lower price-to-earnings ratio than Emblem, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emblem$5.71M43.02-$24.81M-$0.19N/A
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A

In the previous week, Emblem and Emblem both had 1 articles in the media. Helix BioPharma's average media sentiment score of 1.38 beat Emblem's score of 0.67 indicating that Helix BioPharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Emblem
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Helix BioPharma
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Emblem's return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
EmblemN/A N/A N/A
Helix BioPharma N/A -21.54%-279.98%

0.0% of Helix BioPharma shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Emblem beats Helix BioPharma on 5 of the 9 factors compared between the two stocks.

How does Helix BioPharma compare to Theratechnologies?

Helix BioPharma (TSE:HBP) and Theratechnologies (TSE:TH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

Theratechnologies has higher revenue and earnings than Helix BioPharma. Helix BioPharma is trading at a lower price-to-earnings ratio than Theratechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A
TheratechnologiesC$84.38M2.44-C$1.96M-C$0.19N/A

In the previous week, Helix BioPharma and Helix BioPharma both had 1 articles in the media. Helix BioPharma's average media sentiment score of 1.38 beat Theratechnologies' score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Helix BioPharma
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Theratechnologies
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Helix BioPharma has a beta of 0.421776, meaning that its stock price is 58% less volatile than the broader market. Comparatively, Theratechnologies has a beta of 0.256166, meaning that its stock price is 74% less volatile than the broader market.

Helix BioPharma has a net margin of 0.00% compared to Theratechnologies' net margin of -11.81%. Theratechnologies' return on equity of 16.59% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -21.54% -279.98%
Theratechnologies -11.81%16.59%5.15%

0.0% of Helix BioPharma shares are owned by institutional investors. Comparatively, 0.5% of Theratechnologies shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by company insiders. Comparatively, 1.2% of Theratechnologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Theratechnologies beats Helix BioPharma on 6 of the 11 factors compared between the two stocks.

How does Helix BioPharma compare to BriaCell Therapeutics?

Helix BioPharma (TSE:HBP) and BriaCell Therapeutics (CVE:BCT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

BriaCell Therapeutics' return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -21.54% -279.98%
BriaCell Therapeutics N/A N/A N/A

Helix BioPharma is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A
BriaCell TherapeuticsN/AN/AN/A-C$0.38N/A

0.0% of Helix BioPharma shares are held by institutional investors. 2.2% of Helix BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Helix BioPharma had 1 more articles in the media than BriaCell Therapeutics. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for BriaCell Therapeutics. Helix BioPharma's average media sentiment score of 1.38 beat BriaCell Therapeutics' score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the media.

Company Overall Sentiment
Helix BioPharma Positive
BriaCell Therapeutics Neutral

Summary

Helix BioPharma beats BriaCell Therapeutics on 5 of the 8 factors compared between the two stocks.

Get Helix BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for HBP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HBP vs. The Competition

Export
MetricHelix BioPharmaBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$106.93MC$516.65MC$7.18BC$13.07B
Dividend Yield1.50%3.88%2.66%6.18%
P/E Ratio-35.003.0928.0236.51
Price / SalesN/A6,669.11538.9910.34
Price / Cash11.3213.1349.2682.29
Price / Book7.2888.6710.964.52
Net Income-C$50.55M-C$96.07MC$3.57BC$299.09M
7 Day Performance-3.45%0.17%2.12%1.85%
1 Month Performance-11.39%2.10%5.25%1.71%
1 Year Performance44.33%68.02%33.29%36.40%

Helix BioPharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HBP
Helix BioPharma
N/AC$1.40
+2.2%		N/A+44.3%C$106.93MN/AN/A9
PLI
ProMetic Life Sciences
N/AN/AN/AN/AC$317.06MC$39.91MN/A487
ABCN
VIVO Cannabis
N/AC$1.32
+5.6%		N/A+0.0%C$256.62MN/AN/AN/A
EMC
Emblem
N/A$1.88
+1.6%		N/A+0.0%$245.45M$5.71MN/AN/A
TH
Theratechnologies
N/AC$4.47
-4.9%		N/A+6.9%C$205.53MC$84.38MN/A103

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:HBP) was last updated on 7/5/2026 by MarketBeat.com Staff.
From Our Partners
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel